Destruction of prions using vibriolysin or variants thereof

Details for Australian Patent Application No. 2008202345 (hide)

Owner BioMarin Pharmaceutical Inc.

Inventors Kakkis, Emil D

Agent Wrays

Pub. Number AU-A-2008202345

Parent 2002257295

Filing date 28 May 2008

Wipo publication date 19 June 2008

International Classifications

A61L 2/18 (2006.01) Disinfection or sterilising - Liquid substances

A61K 38/46 (2006.01) Medicinal preparations containing peptides

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61L 2/00 (2006.01) Disinfection or sterilising

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/14 (2006.01) Drugs for disorders of the nervous system

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

12 June 2008 Complete Application Filed

19 June 2008 Application Open to Public Inspection

  Published as AU-A-2008202345

29 January 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008202346-Method of manufacturing an amorphous/crystalline silicon heterojunction solar cell

2008202344-A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby